Search Results - "Bastholt, Lars"

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial.

Authors: Overgaard, Jens Hansen, Hanne Sand Specht, Lena et al.

Source: Lancet. 9/20/2003, Vol. 362 Issue 9388, p933-940. 8p. 1 Diagram, 2 Charts, 5 Graphs.

Subjects: Cancer treatment, Radiotherapy, Medical radiology, Hospital radiological services, Phonology, Tumors, Cancer, Clinical trials

Esthesioneuroblastoma: What is the Optimal Treatment?

Authors: Eriksen, Jesper G. Bastholt, Lars Krogdahl, Annelise S. et al.

Source: Acta Oncologica. 2000, Vol. 39 Issue 2, p231-235. 5p. 4 Charts, 1 Graph.

Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences.

Authors: Tolstrup, Lærke K Pappot, Helle Bastholt, Lars et al.

Source: Journal of Medical Internet Research; Apr2020, Vol. 22 Issue 4, p1-N.PAG, 11p, 1 Diagram, 1 Chart, 1 Graph

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.

Authors: Bastholt, Lars Schmidt, Henrik Bjerregaard, Jon Kroll et al.

Source: European Journal of Cancer. Sep2019, Vol. 119, p122-131. 10p.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.

Authors: Bastholt, Lars Svane, Inge Marie Bjerregaard, Jon Kroll et al.

Source: European Journal of Cancer. Jul2019, Vol. 115, p61-67. 7p.

Stabilization of circulating thyroglobulin mRNA transcripts in patients treated for differentiated thyroid carcinoma.

Authors: Feddersen, Søren Bastholt, Lars Pedersen, Susanne M.

Source: Annals of Clinical Biochemistry. Sep2017, Vol. 54 Issue 5, p558-566. 9p. 1 Chart, 3 Graphs.

Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck

Authors: Bastholt, Lars Specht, Lena Jensen, Kenneth et al.

Source: Radiotherapy & Oncology. Oct2007, Vol. 85 Issue 1, p24-28. 5p.

Subjects: Pharmacokinetics, Patients, Tumors, Medical care

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors: Brose, Marcia S. Nutting, Christopher M. Jarzab, Barbara et al.

Source: Lancet. 7/26/2014, Vol. 384 Issue 9940, p319-328. 10p. 1 Diagram, 2 Charts, 2 Graphs.

Subjects: Therapeutic use of iodine isotopes, Thyroid cancer, Cancer treatment, Metastasis, Genetics, Prognosis

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

Authors: Leboulleux, Sophie Bastholt, Lars Krause, Thomas et al.

Source: Lancet Oncology. Sep2012, Vol. 13 Issue 9, p897-905. 9p.

Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites.

Authors: Tinning, Anne Robdrup Bengtsen, Camilla Jensen, Niels Viggo et al.

Source: Hypertension (0194911X). Mar2018, Vol. 71 Issue 3, p473-480.

The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.

Authors: Frary, Evan Gad, Dorte Bastholt, Lars et al.

Source: EJNMMI Research. 10/5/2016, Vol. 6 Issue 1, p1-9. 9p.

Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF -mutant metastatic melanoma: a real-world propensity score–matched survival analysis.

Authors: Garitaonaindia, Yago Khan, Shawez Friis, Rasmus et al.

Source: JNCI: Journal of the National Cancer Institute. Feb2026, Vol. 118 Issue 2, p261-268. 8p.

Seasonal variation in effect of anti‐PD‐1 initiation on overall survival among patients with advanced melanoma.

Authors: Ellebaek, Eva Schina, Aimilia Schmidt, Henrik et al.

Source: Pigment Cell & Melanoma Research. Mar2023, Vol. 36 Issue 2, p224-231. 8p.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Authors: Noringriis, Inge Mansfield Donia, Marco Madsen, Kasper et al.

Source: British Journal of Cancer. Aug2025, Vol. 133 Issue 3, p337-345. 9p.

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.

Authors: Fink, Morten Vittrup, Anders Schwartz Bastholt, Lars et al.

Source: Cancers. Nov2021, Vol. 13 Issue 21, p5550. 1p.

The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma.

Authors: Andersen, Jesper A. S. Spatzek, Anders D. Vilstrup, Mie H. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jun2022, Vol. 49 Issue 7, p2342-2351. 10p. 1 Color Photograph, 3 Charts, 4 Graphs.

Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general population.

Authors: Ismail, Hafsa Helby, Jens Hölmich, Lisbet R. et al.

Source: Pigment Cell & Melanoma Research. Sep2021, Vol. 34 Issue 5, p946-954. 9p.

Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.

Authors: Soerensen, Anne Vest Ellebaek, Eva Bastholt, Lars et al.

Source: Cancers. Sep2020, Vol. 12 Issue 9, p2591. 1p.

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Authors: Døssing, Rasmus Haunstrup Hesselberg, Elisabeth Clausen, Anna Burton et al.

Source: European Journal of Cancer. Jun2026, Vol. 242, pN.PAG-N.PAG. 1p.

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.

Authors: Brose, Marcia S. Capdevila, Jaume Elisei, Rossella et al.

Source: Endocrine-Related Cancer. Aug2024, Vol. 31 Issue 8, p12-24. 13p.